Patents Assigned to NATIONAL CEREBRAL & CARDIOVASCULAR CENTER
-
Patent number: 11925633Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.Type: GrantFiled: December 18, 2020Date of Patent: March 12, 2024Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Tadamasa Matsumoto, Masafumi Ihara, Satoshi Saito, Masanori Fukushima
-
Publication number: 20230416823Abstract: The present invention chiefly aims to provide a new method of detecting or determining ApoE genetic polymorphism, that is rapid and less invasive to the subject. The present invention includes, for example, a method for detecting a genetic polymorphism of apolipoprotein E present in genomic DNA collected from a subject, comprising the following steps 1 to 3: 1. a step of preparing a specimen with DNA released from saliva; 2. a step of adding the followings to the specimen containing the DNA and then mixing: (1) a PCR enzyme, (2) a PCR primer pair for amplifying a nucleic acid fragment of the apolipoprotein E gene, and (3) a fluorescent labeled probe set which has oligonucleotides for detecting the genetic polymorphism of apolipoprotein E; and 3. a step of performing PCR, and measuring the fluorescence intensities according to the genetic polymorphism of apolipoprotein E from the PCR product.Type: ApplicationFiled: October 6, 2021Publication date: December 28, 2023Applicants: Shimadzu Corporation, National Cerebral and Cardiovascular CenterInventors: Daisuke Kawakami, Masafumi Ihara
-
Publication number: 20230380704Abstract: A blood pressure monitoring apparatus including a linear relationship storage portion storing previously stored linear relationships, a blood pressure measurement portion measuring a real arterial pressure of the person to be measured, a proper relationship generation portion applying, for the person to be measured, the real arterial pressure, real compression pressures, and real pulse wave propagation velocities, to thereby generate a proper relationship on the person to be measured among the real arterial pressures of the person to be measured, the real compression pressures, and the real pulse wave propagation velocities, and a blood pressure estimation portion applying, for the person to be measured, the real compression pressures and the real pulse wave propagation velocities obtained under the real compression pressures, to the proper relationship on the person to be measured, to thereby estimate the estimated arterial pressure.Type: ApplicationFiled: October 11, 2021Publication date: November 30, 2023Applicants: A&D COMPANY, LIMITED, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Naotaka HASEBE, Shohei MORODOME, Masaki FURUKOSHI, Kazunori UEMURA, Masaru SUGIMACHI, Takuya NISHIKAWA
-
Publication number: 20230270737Abstract: The present disclosure provides a method of preventing or delaying the progression from mild cognitive impairment (MCI) to dementia or a therapeutic agent therefor.Type: ApplicationFiled: May 6, 2021Publication date: August 31, 2023Applicants: Shimadzu Corporation, National Cerebral and Cardiovascular CenterInventors: Daisuke Kawakami, Masafumi Ihara, Satoshi Saito
-
Patent number: 11697797Abstract: The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises producing a coated region in which a culturing surface is coated with a temperature-responsive polymer or a temperature-responsive polymer composition, forming a droplet of a cell suspension in the coated region, and performing cell culturing in the droplet. A surface zeta potential of the coated region is 0 mV to 50 mV.Type: GrantFiled: September 7, 2021Date of Patent: July 11, 2023Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Yasuhide Nakayama, Ryosuke Iwai, Yasushi Nemoto
-
Publication number: 20230192784Abstract: The technology relates to a method for inducing cardiomyogenesis comprising administering a therapeutically effective amount of either or both of KLF1 and KLF2b to increase the level of KLF1 and/or KLF2b in the cardiomyocytes thereby inducing cardiomyogenesis.Type: ApplicationFiled: July 30, 2020Publication date: June 22, 2023Applicants: Victor Chang Cardiac Research Institute, National Cerebral and Cardiovascular CenterInventors: Kazu Kikuchi, III, Masahito Ogawa
-
Publication number: 20230113556Abstract: The present invention provides an antisense oligomer having the base sequence depicted in SEQ ID NO: 26, an antisense oligomer having a base sequence resulting from substitution, deletion, insertion, or addition of 1 to 6 bases in the base sequence depicted in SEQ ID NO: 26, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, an oligonucleotide conjugate in which the antisense oligomer is bound with a molecule capable of binding to an asialoglycoprotein receptor, and a pharmaceutical composition containing the same.Type: ApplicationFiled: March 26, 2021Publication date: April 13, 2023Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, OSAKA UNIVERSITYInventors: Mariko SHIBA, Tsuyoshi YAMAMOTO, Fumito WADA, Tadayuki KOBAYASHI, Keisuke TACHIBANA, Satoshi OBIKA
-
Publication number: 20220401043Abstract: A cerebral infarction treatment support system (100) includes a detection device (10), a display (30), and an image controller (20), and the image controller (20) includes a receiver (21) configured to receive at least one of first information (41) generated by the detection device (10) or second information (42) related to a susceptibility gene generated based on the first information (41), and a video output (22) configured to output at least one of the received first information (41) or second information (42) to the display (30).Type: ApplicationFiled: October 28, 2020Publication date: December 22, 2022Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, SHIMADZU CORPORATIONInventors: Masafumi IHARA, Takeshi YOSHIMOTO, Daisuke KAWAKAMI
-
Publication number: 20220370510Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.Type: ApplicationFiled: July 29, 2022Publication date: November 24, 2022Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
-
Patent number: 11464441Abstract: A myocardial excitation complementation/visualization apparatus includes an acquiring section that acquires intracardiac electrocardiograms of a subject, the intracardiac electrocardiograms being recorded by a recording unit having a plurality of electrodes, a processing section that performs a computation for completing and visualizing a state of excitation in a myocardium of the subject based on the intracardiac electrocardiograms, and a displaying section that displays the state of excitation in the myocardium of the subject based on an output of the processing section. The processing section includes a first generating section, a correcting section, a second generating section, and a third generating section. The displaying section displays a change of the state of excitation in the myocardium of the subject based on the visualized data.Type: GrantFiled: March 25, 2020Date of Patent: October 11, 2022Assignees: SHIGA UNIVERSITY OF MEDICAL SCIENCE, NIHON KOHDEN CORPORATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Takashi Ashihara, Koji Takizawa, Tatsuo Nishihara, Nobuhiro Suzuki, Yuuho Iwanaga, Akio Ota, Takeshi Tsuchiya, Kazuo Nakazawa, Shin Inada
-
Publication number: 20220265603Abstract: The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.Type: ApplicationFiled: June 24, 2020Publication date: August 25, 2022Applicants: NATIONAL HOSPITAL ORGANIZATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Advanced Innovation Development Co., Ltd., FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Noriko ASAHARA, Takayuki INOUE, Masashi TANAKA, Masafumi IHARA, Satoshi SAITO
-
Publication number: 20220226512Abstract: Composite particles, each of which is obtained by forming, on the surface of a gadolinium oxide-containing particle, a cover film that contains a polymer obtained by polymerizing a monomer component containing a monomer having an ethylenically unsaturated bond; a macrophage imaging agent which contains the composite particles; and a method for producing composite particles, wherein a monomer component containing a monomer having an ethylenically unsaturated bond and gadolinium oxide-containing particles are mixed with each other, and after emulsifying the thus-obtained monomer component-containing mixture in water in the presence of a surfactant and a polymerization initiator in water, the monomer component is polymerized, thereby forming cover films on the surfaces of the gadolinium oxide-containing particles.Type: ApplicationFiled: May 27, 2020Publication date: July 21, 2022Applicants: KYOTO UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JSR CORPORATIONInventors: Teruyuki KONDO, Yu KIMURA, Aoi SON, Tetsuya MATSUDA, Hirohiko IMAI, Hirokazu KOSEKI, Tomohiro AOKI, Katsuyuki TAKASE, Masaaki MIYAJI, Koji TAMORI, Takeaki MASUDA, Hirokazu KAI
-
Patent number: 11389486Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: GrantFiled: July 11, 2019Date of Patent: July 19, 2022Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
-
Publication number: 20220196681Abstract: The present invention is intended to provide a novel biomarker for detecting arteriosclerosis-related disease or for evaluating the stage of progression of arteriosclerosis, and specifically, the present invention relates to a marker for detecting arteriosclerosis-related disease or for evaluating the stage of progression of arteriosclerosis, comprising an NPC2 (Niemann-Pick disease type C2) protein and/or an IGFBP7 (Insulin-like growth factor-binding protein 7) protein.Type: ApplicationFiled: March 29, 2019Publication date: June 23, 2022Applicants: Eiken Kagaku Kabushiki Kaisha, National Cerebral and Cardiovascular CenterInventors: Naoto MINAMINO, Hiroaki YAGI, Mitsuhiro NISHIGORI, Hatsue UEDA, Hitoshi MATSUDA, Yusuke MURAKAMI
-
Publication number: 20220178945Abstract: The present invention is intended to provide a novel biomarker capable of detecting aortic aneurysm with high sensitivity, and specifically, the present invention relates to a detection marker of aortic aneurysm, comprising an NPC2 (Niemann-Pick disease type C2) protein and/or an IGFBP7 (Insulin-like growth factor-binding protein 7) protein.Type: ApplicationFiled: March 29, 2019Publication date: June 9, 2022Applicants: EIKEN KAGAKU KABUSHIKI KAISHA, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Naoto MINAMINO, Hiroaki YAGI, Mitsuhiro NISHIGORI, Hatsue UEDA, Hitoshi MATSUDA, Yusuke MURAKAMI
-
Patent number: 11273222Abstract: Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4? and 2? positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.Type: GrantFiled: May 24, 2018Date of Patent: March 15, 2022Assignee: National Cerebral and Cardiovascular CenterInventors: Mariko Harada-Shiba, Fumito Wada, Satoshi Obika, Tsuyoshi Yamamoto, Keisuke Tachibana, Tadayuki Kobayashi, Kosuke Ito, Motoki Sawamura
-
Patent number: 11253626Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.Type: GrantFiled: January 30, 2018Date of Patent: February 22, 2022Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JMS CO., LTD.Inventors: Tetsuji Yamaoka, Maria Chiara Munisso, Atsushi Mahara, Takashi Yamamoto
-
Publication number: 20220000949Abstract: An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.Type: ApplicationFiled: September 25, 2019Publication date: January 6, 2022Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, KABUSHIKI KAISHA YAKULT HONSHAInventors: Kenji KANGAWA, Takashi NOJIRI, Motofumi KUMAZOE, Yasutake TANAKA, Yoshiyuki SHISHIDO, Takashi ASAHARA, Takahito MIURA, Keisuke TANIGUCHI
-
Publication number: 20210395688Abstract: The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises a preparation step of preparing, on a culturing surface of a cell culture container, a first coated region coated with a temperature-responsive polymer and/or a temperature-responsive polymer composition, and a plurality of second coated regions located at an edge of the first coated region and coated with a cell adhesive substance; and a seeding and culturing step of seeding cells in the first coated region and the second coated regions and culturing the cells to produce a cell structure.Type: ApplicationFiled: September 7, 2021Publication date: December 23, 2021Applicant: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Yasuhide NAKAYAMA, Ryosuke IWAI, Yasushi NEMOTO
-
Publication number: 20210395687Abstract: The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises producing a coated region in which a culturing surface is coated with a temperature-responsive polymer or a temperature-responsive polymer composition, forming a droplet of a cell suspension in the coated region, and performing cell culturing in the droplet. A surface zeta potential of the coated region is 0 mV to 50 mV.Type: ApplicationFiled: September 7, 2021Publication date: December 23, 2021Applicant: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Yasuhide NAKAYAMA, Ryosuke IWAI, Yasushi NEMOTO